← Browse by Condition
Medical Condition

recurrent endometrial carcinoma

Total Trials
2
Recruiting Now
2
Trial Phases
Phase 3, Phase 2

ClinicalMetric tracks all active clinical trials for recurrent endometrial carcinoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — recurrent endometrial carcinoma Clinical Trials

How many clinical trials are currently recruiting for recurrent endometrial carcinoma?
ClinicalMetric currently tracks 2 actively recruiting clinical trials for recurrent endometrial carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 2. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for recurrent endometrial carcinoma?
recurrent endometrial carcinoma research spans Phase 2 (1 trial), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a recurrent endometrial carcinoma clinical trial?
Eligibility criteria for recurrent endometrial carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Phase 3
1
Top Sponsors
National Cancer Institute (NCI) 2 trials

Recruiting Clinical Trials

NCT07198074 Phase 3
Recruiting
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Enrollment
255 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT05112601 Phase 2
Recruiting
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Enrollment
81 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →

Related Conditions

advanced endometrial carcinoma (1) endometrial adenocarcinoma (1) endometrial clear cell adenocarcinoma (1) endometrial dedifferentiated carcinoma (1) endometrial endometrioid adenocarcinoma (1) endometrial mixed cell adenocarcinoma (1) endometrial mucinous adenocarcinoma (1) endometrial undifferentiated carcinoma (1) endometrioid adenocarcinoma (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology